US92764N1028 - Common Stock
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (5/17/2024, 7:00:02 PM)
After market: 9.73 0 (0%)9.73
-0.2 (-2.01%)
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 576 full-time employees. The company went IPO on 2019-10-11. The firm has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The firm also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158
P: 14159064324
CEO: George Scangos
Employees: 576
Website: https://www.vir.bio/
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the first quarter of 2...
Here you can normally see the latest stock twits on VIR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: